Omaxe swings to standalone profit but posts consolidated loss in Q2

Omaxe Ltd has reported a standalone net profit of ₹50.49 crore for the quarter ended 30 September 2026, its second quarter of FY27. The company's board met on 27 October 2026 to consider the unaudited standalone and consolidated results for the quarter and the half year. The same results show a consolidated net loss of ₹25.14 crore for the quarter.

Standalone profit, consolidated loss

The gap between the two sets of numbers is the main point of the quarter. The standalone business, which covers the parent company's own operations, moved into profit. The consolidated figure, which adds subsidiaries and joint ventures, remained in the red.

The consolidated loss was smaller than the ₹166.61 crore loss reported for the corresponding quarter of the previous year. On that comparison, the group's loss narrowed by a wide margin, although it has not yet turned into a profit.

The company's filing does not give management commentary on the quarter's numbers, and no named executive has been quoted on them. Revenue is not part of this report, because the figures available for the quarter have not been reconciled with each other.

SEBI order on public shareholding

On 24 September 2026, the Securities and Exchange Board of India passed an order against Omaxe concerning non-compliance with minimum public shareholding requirements. Listed companies must keep a minimum share of their equity in public hands. A breach can lead to regulatory action and can weigh on how investors view a company.

The company said it is evaluating legal remedies against the order. It also said it does not expect a material impact on its financial position. No deadline for that step has been published.

What investors will watch

• Whether Omaxe files a legal challenge to the SEBI order, and within what time frame.
• Whether the consolidated loss narrows further in the next quarter, and whether the subsidiaries that drive it show improvement.
• Any further regulatory direction arising from the September order.

For buyers, the results do not directly change any project's timeline or price. The regulatory matter, however, concerns the company's listing compliance, and buyers who have booked with Omaxe may want to follow how the company responds to the order. The trading window for insiders closes on 29 October 2026, which means the company will be in a quiet period on its shares until the results are fully digested.